Publications

The journal of pathology. Clinical research

Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.

01-05-2021

BMJ open

First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II).

30-03-2021

European journal of cancer (Oxford, England : 1990)

Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.

01-02-2021

The Journal of molecular diagnostics : JMD

Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.

01-12-2020

Oncoimmunology

Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis.

13-10-2020

The European journal of health economics : HEPAC : health economics in prevention and care

Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN).

01-09-2020

BMC cancer

Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.

20-08-2020

International journal of molecular sciences

Silencing Core Spliceosome Sm Gene Expression Induces a Cytotoxic Splicing Switch in the Proteasome Subunit Beta 3 mRNA in Non-Small Cell Lung Cancer Cells.

12-06-2020

Scientific reports

Performance of four platforms for KRAS mutation detection in plasma cell-free DNA: ddPCR, Idylla, COBAS z480 and BEAMing.

15-05-2020

International journal of cancer

Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression.

01-04-2020

The Journal of pathology

Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progression.

01-03-2020

Nature communications

White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer.

27-01-2020

Molecular aspects of medicine

Circulating biomarkers for early detection and clinical management of colorectal cancer.

01-10-2019

BMC gastroenterology

Prognostic value of microvessel density in stage II and III colon cancer patients: a retrospective cohort study.

16-08-2019

BMJ open

Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC).

27-07-2019

Nature

Genome-wide cell-free DNA fragmentation in patients with cancer.

01-06-2019

BMC cancer

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).

25-04-2019

Cell

Widespread and Functional RNA Circularization in Localized Prostate Cancer.

07-02-2019

The Journal of pathology

Consensus molecular subtype classification of colorectal adenomas.

01-11-2018

Cancer prevention research (Philadelphia, Pa.)

Evaluation of Cancer-Associated DNA Copy Number Events in Colorectal (Advanced) Adenomas.

01-07-2018

Oncotarget

MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer.

29-06-2018

Scientific reports

Aurora kinase A (AURKA) interaction with Wnt and Ras-MAPK signalling pathways in colorectal cancer.

14-05-2018

The British journal of surgery

Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases.

01-01-2018

Annals of internal medicine

Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study.

19-12-2017

F1000Research

Systematically linking tranSMART, Galaxy and EGA for reusing human translational research data.

11-11-2017

Molecular & cellular proteomics : MCP

Identification of Differentially Expressed Splice Variants by the Proteogenomic Pipeline Splicify.

01-10-2017

Science translational medicine

Direct detection of early-stage cancers using circulating tumor DNA.

16-08-2017

F1000Research

GeneBreak: detection of recurrent DNA copy number aberration-associated chromosomal breakpoints within genes.

20-07-2017

PloS one

Lumican and versican protein expression are associated with colorectal adenoma-to-carcinoma progression.

10-05-2017

British journal of cancer

Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.

06-12-2016

Oncotarget

Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.

08-11-2016

Oncogene

Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion.

06-10-2016

Oncogene

CFTR is a tumor suppressor gene in murine and human intestinal cancer.

11-08-2016

The British journal of radiology

The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis.

01-07-2016

Cancer informatics

The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care.

28-06-2016

International journal of cancer

Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.

01-03-2016

Oncotarget

A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9.

12-01-2016

Nuclear medicine and biology

Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237).

01-01-2016

Oncotarget

MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients.

22-09-2015

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Microsimulation Model For The Assessment Of Personalized Cancer Care: The Mapcca Model Framework.

01-11-2014

Journal of the National Cancer Institute

Complexity of lung cancer modifiers: mapping of thirty genes and twenty-five interactions in half of the mouse genome.

03-10-2001

Cancer research

High frequency of interactions between lung cancer susceptibility genes in the mouse: mapping of Sluc5 to Sluc14.

01-11-1998

Experimental lung research

Genetics of quantitative and qualitative aspects of lung tumorigenesis in the mouse: multiple interacting Susceptibility to lung cancer (Sluc) genes with large effects.

11-07-1998

Nature genetics

Complex interactions of new quantitative trait loci, Sluc1, Sluc2, Sluc3, and Sluc4, that influence the susceptibility to lung cancer in the mouse.

01-12-1996

Cancer research

A gene for susceptibility to small intestinal cancer, ssic1, maps to the distal part of mouse chromosome 4.

15-07-1995

Immunogenetics

A susceptibility gene for alveolar lung tumors in the mouse maps between Hsp70.3 and G7 within the H2 complex.

01-01-1995

Oncogene

Kras-2 alleles, mutations, and lung tumor susceptibility in the mouse--an evaluation.

01-05-1994

Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.

First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II).

Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.

Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.

Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis.

Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN).

Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.

Silencing Core Spliceosome Sm Gene Expression Induces a Cytotoxic Splicing Switch in the Proteasome Subunit Beta 3 mRNA in Non-Small Cell Lung Cancer Cells.

Performance of four platforms for KRAS mutation detection in plasma cell-free DNA: ddPCR, Idylla, COBAS z480 and BEAMing.

Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression.

Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progression.

White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer.

Circulating biomarkers for early detection and clinical management of colorectal cancer.

Prognostic value of microvessel density in stage II and III colon cancer patients: a retrospective cohort study.

Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC).

Genome-wide cell-free DNA fragmentation in patients with cancer.

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).

Widespread and Functional RNA Circularization in Localized Prostate Cancer.

Consensus molecular subtype classification of colorectal adenomas.

Evaluation of Cancer-Associated DNA Copy Number Events in Colorectal (Advanced) Adenomas.

MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer.

Aurora kinase A (AURKA) interaction with Wnt and Ras-MAPK signalling pathways in colorectal cancer.

Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases.

Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study.

Systematically linking tranSMART, Galaxy and EGA for reusing human translational research data.

Identification of Differentially Expressed Splice Variants by the Proteogenomic Pipeline Splicify.

Direct detection of early-stage cancers using circulating tumor DNA.

GeneBreak: detection of recurrent DNA copy number aberration-associated chromosomal breakpoints within genes.

Lumican and versican protein expression are associated with colorectal adenoma-to-carcinoma progression.

Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.

Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.

Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion.

CFTR is a tumor suppressor gene in murine and human intestinal cancer.

The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis.

The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care.

Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.

A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9.

Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237).

MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients.

Microsimulation Model For The Assessment Of Personalized Cancer Care: The Mapcca Model Framework.

Complexity of lung cancer modifiers: mapping of thirty genes and twenty-five interactions in half of the mouse genome.

High frequency of interactions between lung cancer susceptibility genes in the mouse: mapping of Sluc5 to Sluc14.

Genetics of quantitative and qualitative aspects of lung tumorigenesis in the mouse: multiple interacting Susceptibility to lung cancer (Sluc) genes with large effects.

Complex interactions of new quantitative trait loci, Sluc1, Sluc2, Sluc3, and Sluc4, that influence the susceptibility to lung cancer in the mouse.

A gene for susceptibility to small intestinal cancer, ssic1, maps to the distal part of mouse chromosome 4.

A susceptibility gene for alveolar lung tumors in the mouse maps between Hsp70.3 and G7 within the H2 complex.

Kras-2 alleles, mutations, and lung tumor susceptibility in the mouse--an evaluation.

This site uses cookies